相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox
Peter Dubsky et al.
LANCET ONCOLOGY (2021)
Characterization of estrogen receptor-low-positive breast cancer
Fei Fei et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
Christoph Thomssen et al.
BREAST CARE (2021)
Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review
Michael Co et al.
CLINICAL BREAST CANCER (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting
Nahla M. Badr et al.
PATHOBIOLOGY (2020)
Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update
Kimberly H. Allison et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
Guoxuan Gao et al.
BMC CANCER (2020)
Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020
Hamdy A. Azim et al.
BREAST JOURNAL (2020)
Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights
Aristomenis Anestis et al.
MOLECULES (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
Xiuzhi Zhu et al.
SCIENTIFIC REPORTS (2020)
Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline
Kandace P. McGuire et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database
Zhong-Li Du et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature
Xin An et al.
CANCER (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
A. Bardia et al.
ANNALS OF ONCOLOGY (2020)
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
Lin-Yu Xia et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Heritability of Low ER Staining/HER2-Breast Tumors: Are We Missing an Opportunity for Germline Testing?
Leann A. Lovejoy et al.
GENES (2020)
Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Katherine A. Hoadley et al.
CANCER RESEARCH (2020)
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
Hope S. Rugo et al.
JNCI CANCER SPECTRUM (2020)
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni et al.
CANCER RESEARCH (2020)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
C. Boddington et al.
LANCET (2019)
Postmastectomy radiation therapy for triple negative, node-negative breast cancer
Waqar Haque et al.
RADIOTHERAPY AND ONCOLOGY (2019)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
Marija Balic et al.
BREAST CARE (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis
Huan Li et al.
CLINICAL BREAST CANCER (2019)
A systematic review of the international prevalence of BRCA mutation in breast cancer
Nigel Armstrong et al.
CLINICAL EPIDEMIOLOGY (2019)
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Shristi Bhattarai et al.
CANCERS (2019)
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis o 263 Patients Treated With Standard Therapy for Stage I-III Disease
Maria Vittoria Dieci et al.
FRONTIERS IN ONCOLOGY (2019)
Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis
Chao Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
Nusayba A. Bagegni et al.
PLOS ONE (2019)
LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
J Cortés et al.
ANNALS OF ONCOLOGY (2019)
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
Jessa Gilda P. Pandy et al.
BMC CANCER (2019)
Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
Qiang Wu et al.
FRONTIERS IN ONCOLOGY (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer
Yi Yao et al.
CANCER MEDICINE (2019)
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olga Caramelo et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2019)
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
Teresa Gamucci et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy
Thaer Khoury et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes
Yuka Asano et al.
ANTICANCER RESEARCH (2018)
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
Christoph Engel et al.
BMC CANCER (2018)
Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study
Alfred P. Yoon et al.
BREAST (2018)
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Irene L. Wapnir et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R. Copson et al.
LANCET ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
Haixia Chen et al.
FRONTIERS IN PHARMACOLOGY (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S. Loibl et al.
ANNALS OF ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
Benjamin D. Smith et al.
PRACTICAL RADIATION ONCOLOGY (2018)
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
H. S. Han et al.
ANNALS OF ONCOLOGY (2018)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
Tithi Biswas et al.
ONCOTARGET (2017)
PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.
Gun Min Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T. Fujii et al.
ANNALS OF ONCOLOGY (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer
Akiko Chiba et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients
M. A. O'Rorke et al.
CANCER TREATMENT REVIEWS (2016)
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers
Alexandra J. van den Broek et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
Abram Recht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
Lucia Gonzalez-Cortijo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Simon B. Zeichner et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2015)
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates et al.
ANNALS OF ONCOLOGY (2015)
Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study
Nirmala Bhoo-Pathy et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Radiation therapy in the locoregional treatment of triple-negative breast cancer
Meena S. Moran
LANCET ONCOLOGY (2015)
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
Elena Provenzano et al.
MODERN PATHOLOGY (2015)
Regional Nodal Irradiation in Early-Stage Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis
Bernadette A. M. Heemskerk-Gerritsen et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy
A. L. Bane et al.
ANNALS OF ONCOLOGY (2014)
Which threshold for ER positivity? a retrospective study based on 9639 patients
M. Yi et al.
ANNALS OF ONCOLOGY (2014)
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis
Antonis Valachis et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Ines Vaz-Luis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis
Kelly Metcalfe et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors
Jyothi S. Prabhu et al.
JOURNAL OF CANCER (2014)
Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
Zachary S. Zumsteg et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer
D. Gareth R. Evans et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Ki67 and proliferation in breast cancer
Nirmala Pathmanathan et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Radiotherapy Can Improve the Disease-Free Survival Rate in Triple-Negative Breast Cancer Patients with T1-T2 Disease and One to Three Positive Lymph Nodes After Mastectomy
Xingxing Chen et al.
ONCOLOGIST (2013)
Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis
Jin Wang et al.
SURGICAL ONCOLOGY-OXFORD (2013)
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective
F. Penault-Llorca et al.
ANNALS OF ONCOLOGY (2012)
Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy
Shirin Sioshansi et al.
CANCER (2012)
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
Eitan Amir et al.
CANCER TREATMENT REVIEWS (2012)
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Takayuki Iwamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review-Based Consensus Methodology
D. Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey
S. Verma et al.
Current Oncology (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy
Bassam S. Abdulkarim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy
Lori J. Pierce et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prophylactic mastectomy and the timing of breast reconstruction
M. Morrow et al.
BRITISH JOURNAL OF SURGERY (2009)
Impact of Pathological Characteristics on Local Relapse After Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost Versus No Boost Trial
Heather A. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Skin Sparing Mastectomy and Immediate Breast Reconstruction (SSMIR) for early breast cancer: Eight years single institution experience
Ramesh Omranipour et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2008)
Can a subgroup of node-negative breast carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified?
Emin Yildirim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer
LJ Pierce et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation
R Jagsi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy
PT Truong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
分享论文
